Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-64413739
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JNJ-64413739 is a small molecule radioligand developed as a positron emission tomography (PET) tracer for imaging the P2X7 receptor (P2X7R), an ATP-gated ion channel implicated in neuroinflammation and various central nervous system disorders. The compound is typically labeled with fluorine-18 ([18F]) for PET imaging applications. It binds selectively and with high affinity to P2X7R, enabling quantification of receptor expression in the human brain. JNJ-64413739 has been used in preclinical and clinical studies to assess P2X7R distribution, evaluate target engagement by P2X7 antagonists, and guide dose selection for therapeutic agents targeting this receptor[1][2][5][6][7]. The drug was initially developed by Johnson & Johnson.
- Other names
- [18F]JNJ-64413739
02
Targets
P2RX7 (P2X purinoceptor 7)
Beyond the preview
Go deeper on JNJ-64413739.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-64413739.